/
MDGL
$539.54+$12.25 (+2.32%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$11.8B
23M shares
52-week range
$284.02 – $615.00
77% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.27%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$440.16
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $180.1M | $958.4M |
| Cost of revenue | $96.0K | $112.0K | $471.0K | $0 | $0 | $0 | $6.2M | $56.1M |
| Gross profit | −$96.0K | −$112.0K | −$471.0K | $0 | $0 | $0 | $173.9M | $902.3M |
| Gross margin | — | — | — | — | — | — | 96.5% | 94.1% |
| R&D | $25.4M | $72.3M | $184.8M | $205.2M | $245.4M | $272.4M | $236.7M | $388.5M |
| Operating income | −$40.5M | −$95.0M | −$206.3M | −$242.5M | −$293.6M | −$380.5M | −$497.9M | −$300.1M |
| EBITDA | −$32.7M | −$83.8M | −$201.8M | −$241.4M | −$290.9M | −$360.4M | −$450.1M | −$264.5M |
| Net income | −$32.8M | −$83.9M | −$202.2M | −$241.8M | −$295.4M | −$373.6M | −$465.9M | −$288.3M |
| Net margin | — | — | — | — | — | — | -258.6% | -30.1% |
| EPS (diluted) | -2.22 | -4.73 | -13.09 | -14.63 | -17.23 | -19.99 | -21.90 | -12.85 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.5B | $-7.12 | $-9.26–$-5.79 | 8 |
| 2027 | $2.2B | $10.03 | $2.67–$14.11 | 8 |
| 2028 | $3.0B | $27.66 | $17.34–$44.04 | 11 |
| 2029 | $4.0B | $45.34 | $40.05–$51.41 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2954.34
Price
$539.53
Implied upside
+448%
Peer comparison
Madrigal Pharmaceuticals, Inc. Common Stock
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
www.madrigalpharma.com- Employees
- 915
- IPO / List date
- Feb 6, 2007
- HQ
- WEST CONSHOHOCKEN, PA
Held by traders on TradeandTell
No one on the platform currently holds MDGL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 71,870 | $37.6M |
| Bridgewater Associatesas of 2026-03-31 | 3,920 | $2.1M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2016-07-25 | 1-for-35reverse |
Recent trades on TradeandTell
No one on the platform has traded MDGL yet.
